Investments & Markets
-
ABIONYX Pharma Announces Its 2023 Full-Year Financial Results
20% reduction of the annual operating loss Cash position of €4,1 million as of December 31, 2023 TOULOUSE, France & LAKELAND, Mich.–(BUSINESS…
-
Patient Square Capital, a Leading Health Care-Focused Investment Firm, Agrees to Acquire NanoString Technologies
Binding Agreement to Acquire Substantially All NanoString Assets for $220 Million Pending Bankruptcy Court Approval Agreement Represents Major Step in Financial Restructuring…
-
Wynn Resorts Announces Final Results of Tender Offer for Cash by Wynn Las Vegas, LLC for its 5.500% Senior Notes due 2025
LAS VEGAS–(BUSINESS WIRE)–Wynn Resorts, Limited (NASDAQ: WYNN) (“Wynn Resorts”) today announced the final results of the previously announced tender offer (the “Tender…
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 8, 2024, the Compensation Committee of Mirum’s Board of…
-
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Castle’s presentations at AAD include the latest findings from the Company’s ongoing collaboration with the National Cancer Institute’s Surveillance, Epidemiology, and End…
-
TPG RE Finance Trust, Inc. Declares Cash Dividend on Series C Cumulative Redeemable Preferred Stock
NEW YORK–(BUSINESS WIRE)–TPG RE Finance Trust, Inc. (NYSE: TRTX) (“TRTX” or the “Company”) today announced the Company’s Board of Directors declared a…
-
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands,…
-
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders,…
-
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors Enrollment ongoing…
-
Certain DWS Closed-End Funds Declare Monthly Distributions
NEW YORK–(BUSINESS WIRE)–The DWS closed-end funds listed below announced today their regular monthly distributions. Details are as follows: March Monthly Dividends Declaration…
Wealth DFM Talk is our flagship podcast, that fits perfectly into your busy life, bringing the latest insight, analysis, news and interviews to you, wherever you are.
Wealth DFM Talk Podcast – listen to the latest episode
